

NCT03624881 Raw comparison:

Summary:
CHIA has 31 criteria while your personal folder has 34 criteria
Total found criteria: 31/31
Total not Found: 0/31
Total Extra: 3
This trial is VALID



╒════════════════════════════════════════════════════╤════════════════════════════════════════════════════╕
│ CHIA Criteria                                      │ Matching Personal Criteria                         │
╞════════════════════════════════════════════════════╪════════════════════════════════════════════════════╡
│ Symptomatic paroxysmal AF who had at least one AF  │ Symptomatic paroxysmal AF who had at least one AF  │
│ episode electrocardiographically documented within │ episode electrocardiographically documented within │
│ one (1) year prior to enrollment Documentation may │ one (1) year prior to enrollment Documentation may │
│ include electrocardiogram (ECG) Transtelephonic    │ include electrocardiogram (ECG) Transtelephonic    │
│ monitoring (TTM) Holter monitor or telemetry strip │ monitoring (TTM) Holter monitor or telemetry strip │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Failed at least one antiarrhythmic drug (AAD)      │ Failed at least one antiarrhythmic drug (AAD)      │
│ (Class I or III antiarrhythmic drugs) as evidenced │ (Class I or III antiarrhythmic drugs) as evidenced │
│ by recurrent symptomatic AF or intolerable to the  │ by recurrent symptomatic AF or intolerable to the  │
│ AAD                                                │ AAD                                                │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Age 18 years or older                              │ Age 18 years or older                              │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Signed Patient Informed Consent Form (ICF)         │ Signed Patient Informed Consent Form (ICF)         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Able and willing to comply with all pre- post- and │ Able and willing to comply with all pre- post- and │
│ follow-up testing and requirements                 │ follow-up testing and requirements                 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Previous surgical or catheter ablation for atrial  │ Previous surgical or catheter ablation for atrial  │
│ fibrillation                                       │ fibrillation                                       │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Previous cardiac surgery (including CABG) within   │ Previous cardiac surgery (including CABG) within   │
│ the past 6 months (180 days)                       │ the past 6 months (180 days)                       │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Valvular cardiac surgical/percutaneous procedure   │ Valvular cardiac surgical/percutaneous procedure   │
│ (i e ventriculotomy atriotomy and valve repair or  │ (i e ventriculotomy atriotomy and valve repair or  │
│ replacement and presence of a prosthetic valve)    │ replacement and presence of a prosthetic valve)    │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Any carotid stenting or endarterectomy             │ Any carotid stenting or endarterectomy             │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Documented LA thrombus on imaging                  │ Documented LA thrombus on imaging                  │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ LA size > 50 mm (parasternal long axis view)       │ LA size \> 50 mm (parasternal long axis view)      │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ LVEF < 40%                                         │ LVEF \< 40%                                        │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Contraindication to anticoagulation (heparin or    │ Contraindication to anticoagulation (heparin or    │
│ warfarin)                                          │ warfarin)                                          │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ History of blood clotting or bleeding              │ History of blood clotting or bleeding              │
│ abnormalities                                      │ abnormalities                                      │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ PCI/MI within the past 2 months (60 days)          │ PCI/MI within the past 2 months (60 days)          │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Documented thromboembolic event (including TIA)    │ Documented thromboembolic event (including TIA)    │
│ within the past 12 months (365 days)               │ within the past 12 months (365 days)               │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Rheumatic Heart Disease                            │ Rheumatic Heart Disease                            │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Uncontrolled heart failure or NYHA function class  │ Uncontrolled heart failure or NYHA function class  │
│ III or IV                                          │ III or IV                                          │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Severe mitral regurgitation (Regurgitant volume =  │ Severe mitral regurgitation (Regurgitant volume ≥  │
│ 60 mL/beat Regurgitant fraction = 50% and/or       │ 60 mL/beat Regurgitant fraction ≥ 50% and/or       │
│ Effective regurgitant orifice area = 0 40cm2)      │ Effective regurgitant orifice area ≥ 0 40cm2)      │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Awaiting cardiac transplantation or other cardiac  │ Awaiting cardiac transplantation or other cardiac  │
│ surgery within the next 12 months (365 days)       │ surgery within the next 12 months (365 days)       │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Unstable angina                                    │ Unstable angina                                    │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Acute illness or active systemic infection or      │ Acute illness or active systemic infection or      │
│ sepsis                                             │ sepsis                                             │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ AF secondary to electrolyte imbalance thyroid      │ AF secondary to electrolyte imbalance thyroid      │
│ disease or reversible or non-cardiac cause         │ disease or reversible or non-cardiac cause         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Presence of implanted ICD/CRT-D                    │ Presence of implanted ICD/CRT-D                    │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Significant pulmonary disease (e g restrictive     │ Significant pulmonary disease (e g restrictive     │
│ pulmonary disease constrictive or chronic          │ pulmonary disease constrictive or chronic          │
│ obstructive pulmonary disease) or any other        │ obstructive pulmonary disease) or any other        │
│ disease or malfunction of the lungs or respiratory │ disease or malfunction of the lungs or respiratory │
│ system that produces chronic symptoms              │ system that produces chronic symptoms              │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Gastroesophageal Reflux Disease (GERD active       │ Gastroesophageal Reflux Disease (GERD active       │
│ requiring significant intervention not including   │ requiring significant intervention not including   │
│ OTC medication)                                    │ OTC medication)                                    │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Significant congenital anomaly or medical problem  │ Significant congenital anomaly or medical problem  │
│ that in the opinion of the investigator would      │ that in the opinion of the investigator would      │
│ preclude enrollment in this study                  │ preclude enrollment in this study                  │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Women who are pregnant (as evidenced by pregnancy  │ Women who are pregnant (as evidenced by pregnancy  │
│ test if pre-menopausal)                            │ test if pre-menopausal)                            │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Concurrent enrollment in an investigational study  │ Concurrent enrollment in an investigational study  │
│ evaluating another device biologic or drug         │ evaluating another device biologic or drug         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Presence of intracardiac thrombus myxoma tumor     │ Presence of intracardiac thrombus myxoma tumor     │
│ interatrial baffle or patch or other abnormality   │ interatrial baffle or patch or other abnormality   │
│ that precludes vascular access or manipulation of  │ that precludes vascular access or manipulation of  │
│ the catheter                                       │ the catheter                                       │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Life expectancy less than 12 months                │ Life expectancy less than 12 months                │
╘════════════════════════════════════════════════════╧════════════════════════════════════════════════════╛



Everything was Found



╒═════════════════════════════════════════════════════════════════════════════════════════════════════╕
│ Extra Personal Criteria                                                                             │
╞═════════════════════════════════════════════════════════════════════════════════════════════════════╡
│ Subjects who meet any of the following exclusion criteria are not eligible for enrollment           │
├─────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ Must have minimum age of 18 Years                                                                   │
├─────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ Subjects must meet all of the following inclusion criteria to be eligible for participation in this │
│ study                                                                                               │
╘═════════════════════════════════════════════════════════════════════════════════════════════════════╛